Drugs.com - Clinical Trials

Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Population of People Living with Generalized Myasthenia Gravis (gMG) Published in The Lancet Neurology

SPRING HOUSE, Pa., (January 23, 2025) – Johnson & Johnson (NYSE: JNJ) today announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad...

Feb 9, 2025 - 21:44
 0
Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Population of People Living with Generalized Myasthenia Gravis (gMG) Published in The Lancet Neurology
SPRING HOUSE, Pa., (January 23, 2025) – Johnson & Johnson (NYSE: JNJ) today announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad...
Read More

Tags:

Previous Article

Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycreti...

Next Article

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC...

Related Posts

Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies

Phase III Study Shows Xolair May Be More Effective With...

Mar 4, 2025  0

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of Duravyu for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

EyePoint Announces Positive Six-Month Results for the P...

Feb 9, 2025  0

Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA

Chlamydia Vaccine Candidate Granted Fast Track Designat...

Mar 26, 2025  0